Skinome launches pioneering skincare probiotic following collaboration with BioGaia

BioGaia and Skinome have collaborated on the research and development of a product with live bacteria that can improve skin health in a natural way by supporting the skin microbiome. The first product, Skinome Probiotic Concentrate, will be available to consumers from September 2022.

Live probiotic bacteria have the potential to restore the skin microbiome balance and improve skin health. Skinome Probiotic Concentrate combines a strain of live Limosilactobacillus reuteri with a minimal number of skin identical ingredients, such as squalene which has the same structure and characteristics as human sebum to soften, improve elasticity and strengthen the skin barrier.

“Interest is exploding in the skin microbiome, as is the scientific knowledge around it. A growing number of cosmetics and skin products look to address this, but typically contain post-biotics or pre-biotics rather than live probiotic bacteria”, says Lydia Engholm, CEO of Skinome.

Results of a first clinical study with Skinome’s Probiotic Concentrate, performed in 2021, were presented during the summer at Microbiome & Probiotic R&D Business Collaboration Forum, Europe.

“The study shows a range of positive effects on typical symptoms of ageing skin already after 3 weeks of use. These include an improved skin structure and volume, a smoothing of uneven skin texture, such as fine lines, as well as a reduction in pore size”, says Lydia Engholm.

Probiotic Concentrate is Skinome’s first probiotic formulation and intended for people with normal to dry skin. The product will be launched in September 2022, first in Sweden on and, after which other markets will follow.

Collaboration solidified through BioGaia Invest

Following several years of joint research and development, BioGaia invested in Skinome in 2021 through the subsidiary BioGaia Invest.

“Skinome is at the cutting edge of their field with natural skin care products that support the skin’s microbiome. Beyond being a productive research and development collaboration, this is an exciting investment with a strong

connection to our core business”, says Nigel Titford, Head of Business Development at BioGaia AB.

BioGaia Invest is a subsidiary to BioGaia AB with funds to invest into exciting new companies focusing on ground-breaking technologies, services and/ or products that may be directly or indirectly related to BioGaia AB’s business.  Investments so far have been made in Skinome and Boneprox. Boneprox specialises in artificial intelligence in dentistry, creating a competence and diagnostics platform connecting dental care with healthcare.

Skinome is one of the most innovative companies in the Swedish skin care market, marketing a range of fresh skin care products that support the skins microbiome in a natural way. Products are currently available in Europe.

For additional information please contact:

Nigel Titford, Head of Business Development: +46 (0) 8 55 52 93 00

Mikaela Idermark Stern, Corporate Communications manager, +46 (0) 730 95 61 50

About BioGaia

BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm.

Attached documents